Pedro de NORONHA PISSARRA
CEO, Biotecnol SA
Pedro de Noronha Pissarra is the current Chairman & Chief Executive Officer of Biotecnol SA, a well established private biopharmaceutical company developing antibody based therapies for treating life-threatening diseases such as cancer. Biotecnol has operations in Europe, the USA and South Africa.
Prior to his current position he was a Board Member of Vida Rhein Corporation SA - a German-Portuguese joint venture, part of the Rhein Biotech NV Group, dedicated to the development Hepatitis B vaccines and development of other biosimilar products.
Pedro de Noronha Pissarra was the founder of the Portuguese Bio-industries Association (APBio) and got it incorporated into EuropaBio (the European Bioindustries Association). He has been widely recognised as one of the key individuals in establishing and promoting biotechnology as in industry in Portugal.
He was a member of the Superior Counsel for Science, Technology and Innovation of the Portuguese government, where he advised the Minister of Science and Technology on the implementation of the National Innovation Plan, during the mandate of Dr José Manuel Durão Barroso as Prime Minister of Portugal.
Dr. Pedro de Noronha Pissarra obtained both his B.Sc. and Ph.D. in Biotechnology from Kings College London (University of London). He carried out research at several institutions, including the Chemical Engineering Department of Massachusetts Institute of Technology (M.I.T.), Cambridge USA and at the Centre for Process Biotechnology (CPB) of the Technical University of Denmark, Lyngby, Denmark. Following his Doctoral degree he specialised in medical sciences and oncology.
Driving success in a period of worldwide turbulence and uncertainty - how are we coping ( 3.8MB)
If someone says today that "the world has changed", is definitely stating not only the obvious, but making a big understatement! Young companies are facing serious challenges and continuous pressure to deliver, whilst access to resources is increasingly harder and the bar keeps being raised. So how to set-up a sustainable business model, where short-term risk and lack of sustainability is mitigated by the accruing of revenue streams, whilst well executed licensing deals are keeping the long-term perspective, which will yield shareholders value? Here we discuss how non-dilutive funding is leveraging our biotherapeutic assets in-licensed from academia and providing a constant valuation of our activity as well as assets.